Resultados: 2

Maribavir for treating refractory cytomegalovirus infection after transplant

England. National Institute for Health and Care Excellence.

Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant. Commercial arrangement There is a simple discount patient access scheme for maribavir. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisat...

Infecções por Citomegalovirus/tratamento farmacológico, Antivirais/uso terapêutico, Transplante de Células-Tronco Hematopoéticas, Transplante de Órgãos

Texto completo

American Society of Transplantation and Cellular Therapy series 4: Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation

Yong, Michelle; Lynn Shigle, Terri; Kim, Yae-Jean; Carpenter, Paul; Chemaly, Roy; Papanicolaou, Genevefa.

Transplantation and Cellular Therapy; (), 2021

The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy (ASTCT) partnered with its Transplant Infectious Disease Special Interest Group (TID-SIG) to update its 2009 compendium-style infectious disease guidelines for hematopoietic cell transplantation (HCT). A new...

Infecções por Citomegalovirus/tratamento farmacológico, Citomegalovirus/efeitos dos fármacos, Farmacorresistência Viral/efeitos dos fármacos, Transplante de Células-Tronco Hematopoéticas, Antivirais/uso terapêutico, Infecções por Citomegalovirus/diagnóstico

Texto completo